The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials

20252 citationsJournal Articlegold Open Access

Authors

Ping‐Tao Tseng · National Sun Yat-sen University

Bing-Yan Zeng · National Sun Yat-sen University

Chih-Wei Hsu · Chang Gung University

Cheuk‐Kwan Sun · I-Shou University

Mein‐Woei Suen · Asia University

André F. Carvalho · Barwon Health

Brendon Stubbs ·

Abstract

PROSPERO CRD420251003016: The study protocol was approved by the Institutional Review Board of the Tri-Service General Hospital, National Defense Medical Center (TSGHIRB E202516007).

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Neuroendocrine Tumor Research Advances

Publication Details

Published in: Journal of Hematology & Oncology

Volume 18, Issue 1, pp. 109-109

DOI: 10.1186/s13045-025-01750-x

Field-Weighted Citation Impact: 2.62

Command Palette

The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials

Authors

Abstract

Topics & Keywords

Publication Details